No 10Y consistency score for revenue — its stored periods are half-year spaced, so quarter-over-same-quarter consistency is not computed.
Valuation vs own 10Y history: P/S 0.6x · 10Y median 1.0x · 40th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 15
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:16:26.161Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for PMGC Holdings Inc. (ELAB) stock was $3.27 as of Oct 5, 2026, 4:00 PM EDT, down 2.68% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -99.9%
PMGC Holdings Inc. functions as a biopharmaceutical firm, primarily dedicated to sourcing and advancing innovative aesthetic and therapeutic solutions.
Biotechnology · Newport Beach, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2023-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-6.10
vs Estimate
N/A
Revenue
$1.31M
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1ELAB | $1.49M | $3.27 | -2.68% | -99.94% | N/A | N/A | N/A |
| 2CRIS | $1.54M | $0.79 | -1.79% | -97.57% | -81.06% | -59.09% | vs ELAB |
| 3ARTL | $1.36M | $3.51 | -4.62% | -91.59% | -64.27% | N/A | vs ELAB |
| 4CMND | $1.11M | $6.00 | +4.90% | -99.81% | N/A | N/A | vs ELAB |
| 5AMIX | $1.92M | $3.54 | -6.35% | -85.08% | N/A | N/A | vs ELAB |
| 6ASBP | $1.02M | $8.88 | +1.14% | -98.04% | N/A | N/A | vs ELAB |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$3.27
High
N/A
